CAGNONI PABLO J sold $1.9M of INCY

CAGNONI PABLO J (President, Global Head of R&D) sold 15,888 shares of INCYTE CORP (INCY) at $119.70 ($1.90M total) on 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAGNONI PABLO J
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosed sale is pre-arranged under Rule 10b5-1, which generally lowers the probability that the transaction reflects new, nonpublic negative information.

02

Market read

Traders may briefly reassess sentiment around Incyte, but the 10b5-1 structure makes this more of a routine disclosure than a catalyst.

03

What to watch

The article does not state whether the sale was for diversification, tax, or compensation-related liquidity needs; without that context, signal strength is limited.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-04, disclosing a 2026-07-31 insider sale.

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an officer (President, Global Head of R&D).

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows R&D President Pablo J Cagnoni sold 15,888 shares at $119.70 on 2026-07-31 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale with an explicit 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with internal expectations of weaker near-term performance, so traders may watch for follow-on disclosures.

Key entities

  • INCY

    Incyte Corp, the company whose insider transaction is disclosed.

  • Pablo J Cagnoni

    President, Global Head of R&D, who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHighAI 8/10

Incyte Advances Pancreatic and Colorectal Cancer Drug Trials

Incyte Corp. (INCY) is advancing two cancer treatments, INCB161734 and INCA33890, into late-stage trials after early results showed promising responses in pancreatic and colorectal cancers. INCB161734, combined with chemotherapy, showed high response rates in pancreatic cancer, while INCA33890 demonstrated activity in colorectal cancer. The company plans Phase 3 trials with topline results expected in 2028 and 2029, respectively.

$INCYMed

Incyte wins Indian patent injunction just weeks before expiration

Incyte secured an interim injunction in India against Melody Healthcare regarding its ruxolitinib patent, just 11 weeks before the patent's expiration. The Delhi High Court ruled in favor of interim protection due to the patent's remaining validity and lack of competing commercial launch. According to the court, this ruling highlights the availability of interim protection against threatened infringement before a rival's commercial launch.

$INCYMedAI 8/10

Ruxolitinib Cream Well Tolerated in Children With AD

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.